Sphingosine-1-phosphate receptor agonist and antagonist compounds
申请人:Wallace Grier A.
公开号:US20090029947A1
公开(公告)日:2009-01-29
The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.
Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is —CH2— or —C(O)—; R1 is —OH or —OP(O)(OH)2; L is a bond, —CH2—, or —C(O)—; R2 is n-C6-8 alkyl; each R3 is independently selected from Cl and —CH3; and n is zero, 1, or 2; provided that if X is —CH2—, then L is —CH2— or —C(O)—. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
公开了式 (I) 的化合物:(I) 或其盐,其中X是-CH2-或-C(O)-;R1是-OH或-OP(O)(OH)2;L是键、-CH2-或-C(O)-;R2是n-C6-8烷基;每个R3独立地选自Cl和-CH3;以及n是零、1或2;条件是如果X是-CH2-,则L是-CH2-或-C(O)-。还公开了将此类化合物用作 G 蛋白偶联受体 S1P1 选择性激动剂的方法,以及包含此类化合物的药物组合物。这些化合物可用于治疗、预防或减缓各种治疗领域的疾病或失调,如自身免疫性疾病和血管疾病。
WO2008/79382
申请人:——
公开号:——
公开(公告)日:——
SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS
申请人:ABBOTT LABORATORIES
公开号:EP2120575A1
公开(公告)日:2009-11-25
ALKYLPHENYL COMPOUNDS
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20210147357A1
公开(公告)日:2021-05-20
Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is —CH
2
— or —C(O)—; R
1
is —OH or —OP(O)(OH)
2
; L is a bond, —CH
2
—, or —C(O)—; R
2
is n-C
6-8
alkyl; each R
3
is independently selected from Cl and —CH
3
; and n is zero, 1, or 2; provided that if X is —CH
2
—, then L is —CH
2
— or —C(O)—. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor SlP
1
, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.